Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620554
Title:
Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.
Authors:
Selinger, C. P.; Lenti, M. V.; Clark, T.; Rafferty, H.; Gracie, D.; Ford, A. C.; OʼConnor, A.; Ahmad, Tariq; Hamlin, P J.
Abstract:
Virtual biologics clinics are often used to review patients with inflammatory bowel disease receiving biological therapy, with decisions whether to continue, switch, or stop therapy made based on review of symptoms, disease history, and investigations. We aimed to investigate whether therapeutic drug monitoring of infliximab (IFX) trough levels and anti-drug antibodies influences decision making within a virtual biologics clinic.
Citation:
Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease. 2017, 23 (12):2083-2088 Inflamm. Bowel Dis.
Publisher:
Oxford Academic
Journal:
Inflammatory bowel diseases
Issue Date:
Dec-2017
URI:
http://hdl.handle.net/11287/620554
DOI:
10.1097/MIB.0000000000001258
PubMed ID:
29140939
Additional Links:
https://academic.oup.com/ibdjournal/article-lookup/doi/10.1097/MIB.0000000000001258
Type:
Journal Article
Language:
en
ISSN:
1536-4844
Appears in Collections:
Gastroenterology; 2017 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorSelinger, C. P.en
dc.contributor.authorLenti, M. V.en
dc.contributor.authorClark, T.en
dc.contributor.authorRafferty, H.en
dc.contributor.authorGracie, D.en
dc.contributor.authorFord, A. C.en
dc.contributor.authorOʼConnor, A.en
dc.contributor.authorAhmad, Tariqen
dc.contributor.authorHamlin, P J.en
dc.date.accessioned2017-12-07T14:56:15Z-
dc.date.available2017-12-07T14:56:15Z-
dc.date.issued2017-12-
dc.identifier.citationInfliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease. 2017, 23 (12):2083-2088 Inflamm. Bowel Dis.en
dc.identifier.issn1536-4844-
dc.identifier.pmid29140939-
dc.identifier.doi10.1097/MIB.0000000000001258-
dc.identifier.urihttp://hdl.handle.net/11287/620554-
dc.description.abstractVirtual biologics clinics are often used to review patients with inflammatory bowel disease receiving biological therapy, with decisions whether to continue, switch, or stop therapy made based on review of symptoms, disease history, and investigations. We aimed to investigate whether therapeutic drug monitoring of infliximab (IFX) trough levels and anti-drug antibodies influences decision making within a virtual biologics clinic.en
dc.language.isoenen
dc.publisherOxford Academicen
dc.relation.urlhttps://academic.oup.com/ibdjournal/article-lookup/doi/10.1097/MIB.0000000000001258en
dc.rightsArchived with thanks to Inflammatory bowel diseasesen
dc.subjectWessex Classification Subject Headings::Gastroenterologyen
dc.titleInfliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.en
dc.typeJournal Articleen
dc.identifier.journalInflammatory bowel diseasesen
dc.type.versionPublisheden

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.